Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



藥明合聯生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2268)

SUPPLEMENTAL ANNOUNCEMENT CONTINUING CONNECTED TRANSACTIONS

(1) REVISION OF ANNUAL CAPS FOR RELEVANT CCT AGREEMENTS;

(2) RENEWAL OF EXISTING CCT AGREEMENTS;

AND

(3) NEW CONTINUING CONNECTED TRANSACTIONS

Reference is made to the announcement of WuXi XDC Cayman Inc. (the "Company") dated September 22, 2025 in relation to, among others, the entering into of Conjugation Discovery Services Agreement (the "Announcement"). This announcement is published for the purpose of providing supplemental information regarding pricing policies in relation to the Conjugation Discovery Services Agreement. Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

Conjugation Discovery Services Agreement

The service fees charged by the Group will be at rates no more favorable than those rates charged by the Group against the independent third party customers for comparable transactions, and will be determined by the parties through arm's length negotiation based on standard pricing schedule used by the Group for all its customers. When determining the prices set out in the standard pricing schedule, a number of factors that are relevant to the services provided are being taken into account including, but not limited to, (i) the nature, scale, frequency and value of the relevant services; (ii) the complexity of tasks completed by the Group; (iii) the resources spent on providing specific services; and (iv) the fees charged for historical transactions of similar nature and the then prevailing market rates.

With respect to each specific conjugation discovery project, the relevant members of the Group and the WXB Group will further enter into individual purchase order(s)/agreement(s) which provide for specific terms and conditions, e.g., service scope, service fee and other requirements, in accordance with the Conjugation Discovery Services Agreement. The actual amount of service fees to be charged for each project will be determined on the basis of the standard pricing schedule and will be counter-checked and approved by the Group with reference to the historical fees charged by the Group to independent third party customers for transactions of similar type and nature. The proposed service fees will be compared with at least two quotations charged for comparable services, if available. The pricing policy for the Conjugation Discovery Services Agreement will continue to be supervised and monitored by the management and the relevant personnel of the Group to ensure the transactions contemplated thereunder are conducted on normal commercial terms and will be in the interests of the Company and its Shareholders as a whole.

Save as disclosed herein, all the information set out in the Announcement remains unchanged and continues to be valid for all purposes.

By order of the Board
WuXi XDC Cayman Inc.
Dr. Jincai LI
Executive Director and Chief Executive Officer

Hong Kong, November 25, 2025

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincai LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Jijie GU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.

* For identification purpose only